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Abstract
Purpose: Palliative treatment techniques for advanced stage rectal cancer should be designed according to the patients’ major
symptoms. Combined chemo-radiation therapy is effective choice for symptomatic patients with good performance status. In
this study, we reviewed our patients' stage IV rectal carcinoma in regard to most common presentation, outcome and possible
prognostic features. Methods Medical chart of twenty patients who were diagnosed with stage IV rectal carcinoma, were re-
viewed based on the hospital database information, which included images, radiotherapy charts, and their follow up notes.
Results: All patients were young with age less than 40 years. Bleeding per rectum, pain, and symptoms of obstruction were the
most common presentation. Seven patients had solitary lesion and 13 patients had multiple lesions. Eleven patients with multi-
ple metastases were treated with palliative chemotherapy and radiotherapy. Patients who had solitary metastases to liver had a
median survival time of 49 months versus 13.5 months for other patients (p = 0.001). Conclusion: Patients who presented with
solitary liver metastases could be treated with a course of neoadjuvant chemo-radiotherapy similar to the curative one.
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Introduction
Approximately 20% to 30% of patients with rectal cancer
found to have metastatic lesions. Palliative treatment strate-
gy for advanced stage rectal cancer should be individualized
to patients according to performance status, stage and symp-
toms. Chemotherapy for metastatic disease is the standard
therapy for asymptomatic patients.1-4 Symptomatic patients
are considered to a challenge and can be treated with chem-
otherapy or combined chemo-radiation therapy in conjunc-
tion with a surgery, if necessary. The most common presen-
tations of these patients were bleeding per rectum and bowel
obstruction for which they need dedicated plan of palliative
therapy which emphasize on symptoms relief and improving
quality of life. The choice of treatment is mainly dependent
upon the patient’s symptoms, age, co-morbid conditions, and
extent of disease. A multidisciplinary approach which in-
cludes medical oncologist, radiation oncologist, palliative
care and the surgeon of determining wither or not invasive
intervention is indicated.5
The rationale for elective resection in asymptomatic patients
is to prevent further complications. This could develop dur-
ing the treatment course, which may require urgent surgery
associated with higher morbidity and mortality. Recent
agents of chemotherapy showed improvement in prospective
to the survival among patients with stage IV colorectal can-
cer; however, the risks and benefits of a deferred surgical
strategy have not been completely evaluated. Combinations
of fluorouracil/leucovorin with oxaliplatin or irinotecan have
yielded response rates of 50%, disease control rates of 85%,
and a median survival rate of 20 months in prospective clin-
ical trials.6,7 The purpose of this research is to review the
presentation, outcome and prognostic factors for stage IV
rectal patients at our institute.
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Methods and Materials
Patient characteristics
Our group consisted of 90 patients with confirmed histology
of rectal carcinoma presented at our institute between Janu-
ary 2009 to December 2010. For all patients, medical charts,
radiology films, radiotherapy charts and their follow up
notes were reviewed after receiving the approval from Insti-
tutional Ethics Board. Of those patients, only 20 patients
(22.2%) had rectal carcinoma with distant metastases (DM).
History and physical examination of each patient were ob-
tained too. A full staging work up was done for all of the
patients. Metastatic work up included CT chest, abdomen,
and pelvis. Liver tri-phasic computed tomography (CT) and
magnetic resonance imaging (MRI) of liver and bone scan
were performed as necessary. Laboratory investigations in-
cluded count blood cells, liver, and renal profiles. Tumor
markers included carcino-embryonic antigen and CA 19-9.
Chemo-Radiation therapy
Patients underwent CT simulation in a prone position with
distended bladder, belly board, and thermoplastic sheet fixa-
tion. Multiple CT cuts at 0.5 cm interval were obtained
throughout the pelvis. CT data was transferred to the XiO
treatment planning system (version 4.2). On each axial CT
slice, clinical target volume (CTV) and organs at risk (OAR)
were contoured. CTV included the rectum, mesorectum,
internal iliac and pre-sacral lymph nodes. Planning target
volume (PTV) was generated with a 0.5 cm expansion from
the CTV to account for the setup errors. Appropriate field
weighting and beam modifiers (wedges and blocks) were
selected to keep the OAR doses below their tolerance. For
beam arrangement in the treatment plans three-field tech-
nique (a posterior field and two opposed lateral fields) was
used to spare the anterior structures, particularly the small
bowel. All patients were treated by a high energy linear ac-
celerator with photon energies 6 and/or 15 MV. The total
dose was 50.4 Gy/ 28 fractions/ 5.5 weeks. Specifically, the
primary plans had dose prescribed to the PTV with schema
of 45 Gy /25 fractions in 5 weeks. The boost plans had dose
of 5.4 Gy in 3 fractions was delivered to the gross tumor
volume (GTV) plus 2 cm margin. Palliative radiotherapy to
the pelvis (gross tumor plus 2-cm margin) was 30 Gy/ 10
fractions/2 weeks; however, palliative dose to bone was 20
Gy/ 5 fractions /one week. Opposed anterior/ posterior fields
used for the palliative intent. Capcitabine was given concur-
rent with radical radiotherapy by a dose 825 mg/ m2 twice
daily. FOLFOX (fluorouracil, leucovorin, and oxaliplatin)
regimen was given in the adjuvant setting for 4 months as
well as the first line for multiple metastases till progression.
The second line was FOLFIRI (fluorouracil, leucovorin, and
irinotecan) regimen. The median number cycles of chemo-
therapy were 8 cycles for palliative intent. K-ras test was not
available at our institute by that time; therefore, cetuximab
was not used. Dose modification and treatment interruption
were permissible.
Statistical analysis
Kaplan-Meier estimates of actuarial survival and progression
free survival were calculated with Graphed prism program
(version 5). For comparisons of survival differences, the
log-rank test was performed. The p-values were double-sided
with p ≤ 0.05 considered statistically significant.
Results




























































All patients were less than 40 years of age. The patient group
included 13 males and 7 females. Bleeding per rectum, pain,
and bowel obstruction were the most common presenting
symptoms (Table 1). Most of patients presented with multi-
ple symptoms. Rectal biopsy revealed that out of 20 patients,
8 patients had mucoid carcinoma, 1 patient had signed ring
carcinoma while adenocarcinoma was found in 11 patients.
According to TNM staging system, 45% of cases had T4 tu-
mors and 85% had lymph node metastasis at the time of di-
agnosis. Liver represents the most common site of distant
metastases; 7 patients had solitary lesion and 13 patients had
multiple lesions.
Patients who presented with solitary liver lesions treated
with neo-adjuvant chemo-radiation (capcitabine + radio-
therapy) followed by surgery including tumor resection +
metastatectomy then followed by adjuvant chemotherapy. In
regard of radical surgery, 3 patients underwent low anterior
resection and 4 patients underwent abdomen-perineal resec-
tion (APR). Patients who presented with multiple metastases
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were treated with palliative intension. Eleven patients of
them (11 out of 13) were treated with palliative chemother-
apy and palliative radiotherapy (RT). Two patients treated
with best supportive care due to poor performance status.
Palliative APR was done for two out of these 13 patients. No
patient needed late palliative surgery.











FIG.1: Overall Survival Proportion.











FIG. 2: Progression Free Survival.












FIG. 3: Overall Survival of solitary and multiple metastases.
The median follow up period for all patients was 9.5 months
(range 4-60). The median survival for the whole group of
patients was 19 months (Figure 1). The median time of pro-
gression free survival was 9.5 months for all patients (Figure
2). For patients who had solitary liver metastases, the median
survival time was 49 months versus 13.5 months for patients
who had multiple metastases (p = 0.001) (Figure 3).
Discussion
The management of patients with metastatic colo-rectal car-
cinoma is still controversial, while for patients with solitary
hepatic lesions the beneficiary of radical therapy has been
shown. There was no benefit of any radical therapy for pa-
tients with diffuse metastatic spread. Rosen et al. 8 favored an
aggressive approach resection of the primary tumor in all
patients in the absence of extensive metastases or carcino-
matosis. More than two thirds of patients who presented
with synchronous, stage IV colorectal cancer in the United
States underwent up-front surgical resection of their primary
tumors.9,10 Retrospective analyses in the pre-target therapy
era have shown that resection of asymptomatic primary tu-
mors was frequently associated with prolonged survival, but
was not found to significantly reduce the incidence of
life-threatening tumor-related complications.11-13 However,
Poultsides et al 14 demonstrated that 217 patients out of 233
patients (92%) never required surgical palliation of their
primary tumor when received upfront modern combination
chemotherapy. Ten patients (4%) required non-surgical in-
tervention such as stent or RT for symptomatic management
of the primary site. Neither use of bevacizumab, location of
the primary tumor in the rectum, or metastatic disease bur-
den was associated with increased intervention rate. Com-
pared to our sample, only two patients underwent initial
palliative resection.
Upfront surgery has historically been opted for these patients
to prevent acute bowel obstruction, bleeding or perforation.
As well known, an emergent surgery is usually associated
with higher mortality. In our study late surgery was not re-
quired for any of the patients. The rate of late surgical inter-
vention necessary to palliate primary tumor-related events is
7% to 20%. 10,12-14 Other reason for prophylactic surgery was
that patients with low metastatic burden who are presumed
to be at high risk of obstruction because of their relatively
long survival times.8 Other reports, however, have failed to
establish a correlation between advanced disease stage and
the incidence of late primary tumor complications.13,15 Radi-
otherapy or chemo-radiotherapy can be given as palliative
intent. Objective tumor regression can be produced and
symptoms can be relieved. Radiotherapy is particularly ef-
fective for controlling pain, bleeding and discharge but often
less effective for altered bowel habit.16, 17
Patients underwent a palliative treatment have a relatively
short survival duration (median: 6-9 months), with dismal
5-years survival rates (0%-5%).17 This is mainly for patients
who present with symptoms include obstruction, pain,
bleeding and perforation. New evolving regimen of systemic
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therapy have expanded the therapeutic options for these
patients and improved median survival from less than one
year to 20 months or longer. Fewer than 10% of those pa-
tients treated with chemotherapy alone are still alive at five
years 18-21, which is matched with our study. The median
survival for patients with multiple metastases was 13.5
months. No survival advantage is gained by resection of an
asymptomatic primary lesion in the setting of incurable stage
IV colorectal cancer. The median survival was 14.5 months
for patients who underwent tumor resection versus 16.6
months for patients who did not underwent any surgical
resection.11, 18, 22, 23
Liver is the dominant metastatic site for patients with co-
lo-rectal cancer. Twenty percent of patients with isolated
hepatic metastases are candidates to potentially curative re-
section. Still the majority of patients are not surgical candi-
dates because of tumor size, location, multifocality, or inad-
equate hepatic reserve. Resection offers the greatest likeli-
hood of cure for patients with isolated liver metastases.24, 25
In our review, the group who presented with solitary liver
metastases and had metastatectomy achieved a median sur-
vival 49 months. Five-year survival rates after resection
range from 24% to 58%.26-28 Five-year survival rate was 25%
in a population-based retrospective report of 3957 United
State Medicare enrollees undergoing hepatic resection for
colorectal cancer liver metastases.29
The use of 3-dimension conformal radiation therapy
(3DCRT) has been shown to produce less favorable clinical
and dosimetric results when compared to the intensity mod-
ulated radiation therapy (IMRT) and volumetric modulated
arc therapy (VMAT).30, 31 The use of advanced treatment
techniques such as IMRT and VMAT could improve the
clinical results presented in our study. In radiation therapy
planning, accuracy of dose calculation is also equally im-
portant in order to avoid miscalculation of the dose. Since
dose calculation algorithms can affect the clinical and dosi-
metric results in radiation therapy, it is recommended to use
the more accurate dose calculation engines while computing
the cancer treatment plans.32,33
Conclusion
Upfront chemo-radiation may be effective for metastatic
rectal cancer patients to prevent the need of urgent surgery.
Aggressive surgery with chemo-radiation is the hope of cure
for solitary liver metastatic rectal carcinoma.
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